Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The mu opioid receptor (MOR) is a diversely regulated target for the alleviation of pain in the clinical setting. However, untoward side effects such as tolerance, dependence, respiratory suppression, constipation, and abuse liability detract from their usefulness. Studies in genetically modified rodent models suggest that activating G protein signaling pathways while avoiding phosphorylation of the receptor or recruitment of βarrestin scaffolding proteins could preserve the analgesic properties of MOR agonists while avoiding certain side effects. With the development of novel MOR “biased” agonists, which lead to preferential activation of G protein pathways over receptor phosphorylation, internalization or interaction with other effectors, this hypothesis can be tested in a native, physiological setting. Overall, it is clear that the MOR is not a simple on and off switch and that the diverse means by which the receptor can be regulated may present an opportunity to refine therapeutics for the treatment of pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013
Florence, C. S., Zhou, C., Luo, F., & Xu, L. (2016) · Medical Care · doi:10.1097/mlr.0000000000000625 · Cited by 1,152
Structure and dynamics of GPCR signaling complexes
Hilger, D., Masureel, M., & Kobilka, B. K. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-017-0011-7 · Cited by 969
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647 · cited 3×
“In mouse and rat models oliceridine maintained the typical mu opioid attenuation of pain-like responses while demonstrating reductions in gastrointestinal and respiratory side effects (48).”
BackgroundBias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 2×
“4- to 100-fold preference as measured by either GTPγS binding or cAMP accumulation versus either βarrestin2 recruitment PathHunter® enzymatic complementation or recruitment of GFP-conjugated βarrestin2 (59, 60).”
BackgroundViscusi, E. R., Skobieranda, F., Soergel, D. G., Cook, E., Burt, D. A., & Singla, N. (2019) · Journal of Pain Research · doi:10.2147/jpr.s171013 · Cited by 167
Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116689257 · Cited by 166 · cited 2×
“Other studies suggested that oliceridine could produce constipation at higher doses (49).”
BackgroundOptimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71 · cited 1×
“4- to 100-fold preference as measured by either GTPγS binding or cAMP accumulation versus either βarrestin2 recruitment PathHunter® enzymatic complementation or recruitment of GFP-conjugated βarrestin2 (59, 60).”
BackgroundSelf-citation
Research works printed but not linked: 57
- Pasternak, 2018, Mu opioid pharmacology: 40 Years to the promised land, Adv Pharmacol, 82, 261, 10.1016/bs.apha.2017.09.006 · DOI
- Volkow, 2017, The role of science in addressing the opioid crisis, N Engl J Med, 377, 391, 10.1056/NEJMsr1706626 · DOI · Paper page
- Shukla, 2014, Visualization of arrestin recruitment by a G-protein-coupled receptor, Nature, 512, 218, 10.1038/nature13430 · DOI · Paper page
- Gurevich, 2019, The structural basis of the arrestin binding to GPCRs, Mol Cell Endocrinol, 484, 34, 10.1016/j.mce.2019.01.019 · DOI
- Thomsen, 2016, GPCR-G protein-beta-arrestin super-complex mediates sustained G protein signaling, Cell, 166, 907, 10.1016/j.cell.2016.07.004 · DOI · Paper page
- Bohn, 1999, Enhanced morphine analgesia in mice lacking beta-arrestin 2, Science, 286, 2495, 10.1126/science.286.5449.2495 · DOI · Paper page
- Bohn, 2000, Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence, Nature, 408, 720, 10.1038/35047086 · DOI · Paper page
- Bohn, 2004, Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery, Mol Pharmacol, 66, 106, 10.1124/mol.66.1.106 · DOI · Paper page
- Bohn, 2002, Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice, J Neurosci, 22, 10494, 10.1523/JNEUROSCI.22-23-10494.2002 · DOI · Paper page
- Mittal, 2012, Evidence that behavioral phenotypes of morphine in beta-arr2-/- mice are due to the unmasking of JNK signaling, Neuropsychopharmacology, 37, 1953, 10.1038/npp.2012.42 · DOI
- Bu, 2015, Enhancement of morphine analgesia and prevention of morphine tolerance by downregulation of beta-arrestin 2 with antigene RNAs in mice, Int J Neurosci, 125, 56, 10.3109/00207454.2014.896913 · DOI
- Li, 2009, Improvement of morphine-mediated analgesia by inhibition of beta--arrestin-2 expression in mice periaqueductal gray matter, Int J Mol Sci, 10, 954, 10.3390/ijms10030954 · DOI · Paper page
- Yang, 2011, Antinociceptive potentiation and attenuation of tolerance by intrathecal beta-arrestin 2 small interfering RNA in rats, Br J Anaesth, 107, 774, 10.1093/bja/aer291 · DOI
- Butcher, 2011, Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code, J Biol Chem, 286, 11506, 10.1074/jbc.M110.154526 · DOI · Paper page
- Mayer, 2019, Distinct G protein-coupled receptor phosphorylation motifs modulate arrestin affinity and activation and global conformation, Nat Commun, 10, 1261, 10.1038/s41467-019-09204-y · DOI
- Gainetdinov, 2004, Desensitization of G protein-coupled receptors and neuronal functions, Annu Rev Neurosci, 27, 107, 10.1146/annurev.neuro.27.070203.144206 · DOI · Paper page
- Glück, 2014, Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5, Biol Psychiatry, 76, 767, 10.1016/j.biopsych.2014.01.021 · DOI
- Raehal, 2009, Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6, Drug Alcohol Depend, 104, 187, 10.1016/j.drugalcdep.2009.04.011 · DOI
- Kliewer, 2019, Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects, Nat Commun, 10, 367, 10.1038/s41467-018-08162-1 · DOI · Paper page
- Xu, 2017, Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine, J Clin Invest, 127, 1561, 10.1172/JCI88760 · DOI · Paper page
- Raehal, 2011, The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics, Neuropharmacology, 60, 58, 10.1016/j.neuropharm.2010.08.003 · DOI · Paper page
- Terman, 2004, G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal, Br J Pharmacol, 141, 55, 10.1038/sj.bjp.0705595 · DOI · Paper page
- Grecksch, 2011, Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A mu-opioid receptor knock-in mice, J Neurosci, 31, 13890, 10.1523/JNEUROSCI.2304-11.2011 · DOI
- Groer, 2011, Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation, J Biol Chem, 286, 31731, 10.1074/jbc.M111.248310 · DOI · Paper page
- Thompson, 2015, Biased agonism of endogenous opioid peptides at the mu-opioid receptor, Mol Pharmacol, 88, 335, 10.1124/mol.115.098848 · DOI
- Whistler, 1998, Morphine-activated opioid receptors elude desensitization by beta-arrestin, Proc Natl Acad Sci U S A, 95, 9914, 10.1073/pnas.95.17.9914 · DOI · Paper page
- Zhang, 1998, Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness, Proc Natl Acad Sci U S A, 95, 7157, 10.1073/pnas.95.12.7157 · DOI · Paper page
- Wood, 2004, Function of opioids in the enteric nervous system, Neurogastroenterol Motil, 16, 17, 10.1111/j.1743-3150.2004.00554.x · DOI · Paper page
- Briggs, 1995, Oxymorphone-induced analgesia and colonic motility measured in colorectal distension, Pharmacol Biochem Behav, 52, 561, 10.1016/0091-3057(95)00140-R · doi:10.1016/0091-3057(95)00140-r
- Burks, 1987, Brain, spinal cord and peripheral sites of action of enkephalins and other endogenous opioids on gastrointestinal motility, Gastroenterol Clin Biol, 11, 44B
- Raehal, 2005, Morphine side effects in beta-arrestin 2 knockout mice, J Pharmacol Exp Ther, 314, 1195, 10.1124/jpet.105.087254 · DOI · Paper page
- Maguma, 2014, Specific localization of beta--arrestin-2 in myenteric plexus of mouse gastrointestinal tract, PLoS One, 9, 10.1371/journal.pone.0103894 · doi:10.1371/journal.pone.0103894
- Smith, 2012, Morphine decreases enteric neuron excitability via inhibition of sodium channels, PLoS One, 7, 10.1371/journal.pone.0045251 · DOI
- Bohn, 2003, Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice, J Neurosci, 23, 10265, 10.1523/JNEUROSCI.23-32-10265.2003 · DOI · Paper page
- Urs, 2011, A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice, Neuropsychopharmacology, 36, 551, 10.1038/npp.2010.186 · DOI · Paper page
- Beaulieu, 2005, An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior, Cell, 122, 261, 10.1016/j.cell.2005.05.012 · DOI · Paper page
- Schmid, 2010, Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via β-arrestin2/Src/Akt signaling complex in vivo, J Neurosci, 30, 13513, 10.1523/JNEUROSCI.1665-10.2010 · DOI · Paper page
- Masri, 2008, Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics, Proc Natl Acad Sci U S A, 105, 13656, 10.1073/pnas.0803522105 · DOI · Paper page
- Watari, 2014, Multiple functions of G protein-coupled receptor kinases, J Mol Signal, 9, 1
- Stoeber, 2018, A genetically encoded biosensor reveals location bias of opioid drug action, Neuron, 98, 963, 10.1016/j.neuron.2018.04.021 · DOI · Paper page
- Groer, 2007, An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization, Mol Pharmacol, 71, 549, 10.1124/mol.106.028258 · DOI · Paper page
- Lamb, 2012, Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacology, Drug Alcohol Depend, 121, 181, 10.1016/j.drugalcdep.2011.10.026 · DOI
- Tidgewell, 2008, Herkinorin analogues with differential beta-arrestin-2 interactions, J Med Chem, 51, 2421, 10.1021/jm701162g · DOI
- Manglik, 2016, Structure-based discovery of opioid analgesics with reduced side effects, Nature, 537, 185, 10.1038/nature19112 · DOI · Paper page
- Chen, 2013, Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain, J Med Chem, 56, 8019, 10.1021/jm4010829 · DOI · Paper page
- Austin Zamarripa, 2018, The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats, Drug Alcohol Depend, 192, 158, 10.1016/j.drugalcdep.2018.08.002 · DOI
- Liang, 2019, Pharmacological characters of oliceridine, a mu-opioid receptor G-protein-biased ligand in mice, Anesth Analg, 129, 1414, 10.1213/ANE.0000000000003662 · DOI
- Soergel, 2014, Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers, Pain, 155, 1829, 10.1016/j.pain.2014.06.011 · DOI · Paper page
- Soergel, 2014, First clinical experience with TRV130: Pharmacokinetics and pharmacodynamics in healthy volunteers, J Clin Pharmacol, 54, 351, 10.1002/jcph.207 · DOI
- Singla, 2017, A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty, J Pain Res, 10, 2413
- Singla, 2019, APOLLO-2: A randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate to severe acute pain following abdominoplasty, Pain Pract, 19, 715, 10.1111/papr.12801 · DOI · Paper page
- Hill, 2018, The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception, Br J Pharmacol, 175, 2653, 10.1111/bph.14224 · DOI · Paper page
- Varadi, 2016, Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2, J Med Chem, 59, 8381, 10.1021/acs.jmedchem.6b00748 · DOI · Paper page
- Black, 1983, Operational models of pharmacological agonism, Proc R Soc Lond B Biol Sci, 220, 141, 10.1098/rspb.1983.0093 · DOI · Paper page
- Grim, 2019, A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal [published online ahead of print Aug 23], Neuropsychopharmacology
- Schwienteck, 2019, Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats, Neuropharmacology, 150, 200, 10.1016/j.neuropharm.2019.01.020 · DOI
- Ho, 2018, G protein signaling-biased agonism at the kappa-opioid receptor is maintained in striatal neurons, Sci Signal, 11, 10.1126/scisignal.aar4309 · DOI
Cited by
DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141
Vasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55
Mu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53
“Nevertheless, biased MOR agonists offer potential avenues for development of novel therapeutics for chronic pain and for understanding the relationship between biased agonism and in vivo effects; the development of these ligands serves as a strategy for rational opioid drug design, which seeks improved therapeutic ind…”
BackgroundSynaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Metadata
- Authors
- Grim, T. W., Acevedo-Canabal, A., & Bohn, L. M.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 87
- Issue
- 1
- Pages
- 15-21
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2982315497
- Cited by
- 85
- References
- 7
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institute on Drug Abuse (DA038964, DA033073, DA047039)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.